Pegcetacoplan

5 trials 1 recruiting LOncology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

1 Sponsors

9 Countries

Phase III

Phase II

Phase III: 3 Phase II: 2

Indications tested

C3 glomerulopathy 2

Sponsors using this IMP

Apellis Pharmaceuticals Inc. 5

All trials

5 total

A single arm study to evaluate the safety and biological activity of pegcetacoplan in patients 12- 17 years old with paroxysmal nocturnal he… Recruiting

2024-516350-22-00 Phase II 2 countries Apellis Pharmaceuticals Inc.
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolifer… Ended

2023-504625-39-00 Phase III 8 countries Apellis Pharmaceuticals Inc.
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patient… Ended

2024-514130-20-00 Phase III 4 countries Apellis Pharmaceuticals Inc.
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplan… Ended

2024-511544-36-00 Phase II 3 countries Apellis Pharmaceuticals Inc.
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects with Geographic Atrophy Secondary to … Ended

2024-512945-18-00 Phase III 7 countries Apellis Pharmaceuticals Inc.

Showing 1–5 of 5 trials

← All drugs A–Z